Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeckTAR: ctDNA for Residual Disease Prediction in Head and Neck Cancer
NCT05710679Recruiting
- Sponsor
- Centre Jean Perrin
- Start
- Jan 2024
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Open-label, single-arm trial in head and neck squamous cell carcinoma (HNSCC), sponsored by Centre Jean Perrin. Primary endpoint: Rate of patients with incomplete cervical lymph node response on PET-CT after radiochemotherapy having circulating DNA (cDNA) at 3 months. Started Jan 2024; status: recruiting.
02
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05710679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05710679.